# A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC

> **NCT07244705** · PHASE1,PHASE2 · RECRUITING · sponsor: **Anbogen Therapeutics, Inc.** · enrollment: 66 (estimated)

## Conditions studied

- Colorectal Cancer (Diagnosis)
- Colorectal Cancer Metastatic
- Colorectal Cancer (CRC)
- Immunotherapy

## Interventions

- **DRUG:** ABT-301
- **DRUG:** Tislelizumab
- **DRUG:** Bevacizumab (Avastin)

## Key facts

- **NCT ID:** NCT07244705
- **Lead sponsor:** Anbogen Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11
- **Primary completion:** 2028-04
- **Final completion:** 2028-07
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2025-11-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07244705

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07244705, "A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07244705. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*